



Goldline Pharmaceutical Limited

CIN.: L51397MH2004PLC147806

Date: 29th July, 2026

To,
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai – 400001

Scrip Code: 544759, Scrip ID: GLPL

Subject: - Disclosures under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 29(2) of SEBI (SAST) Regulation, 2011, the Company has received a disclosure pursuant to acquisition of equity shares from the open market is as follows:

SR No	Name of the Acquirer	Disclosure dated/ Regulation	No of shares purchased and % of total issued and paid-up share Capital	Remarks
1.	Mr. Prashant Shrikrishna Karkare	Disclosure dated 28 th July, 2026 pursuant to Regulation 29(2) of SEBI (SAST) Regulation, 2011	Acquired 27000 equity shares representing (0.28%) of the total issued and paid-up share capital of the Company	Mr. Prashant Shrikrishna Karkare, Executive Director of the Company has acquired 27000 equity shares as on 28.07.2026 through open market.

We request you to kindly take the above disclosure on your records.

Thanking You,

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi
Company Secretary cum Compliance Officer

To,
Goldline Pharmaceutical Limited

CIN: U51397MH2004PLC147806

Address: 103, F-1 Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar,
Shanidham, Narendra Nagar, Nagpur, Maharashtra, India, 440015.

Subject: Disclosure under Regulation 29 (2) of Securities and Exchange Board of India
(Substantial acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Mam,


I, Prashant Shrikrishna Karkare, Executive Director of the Goldline Pharmaceutical Limited (the "Company") wish to inform you that I have acquired the following shares as below:

Date of Acquisition	No of shares acquired	% of total paid-up shares capital	Mode of acquisition
28 th July, 2026	27000	0.28%	Open market Purchase

The Disclosure in this under Regulation 29 (2) of Securities and Exchange Board of India (Substantial acquisition of Shares and Takeovers) Regulations, 2011 is enclosed herewith.

Kindly acknowledge the receipt.

Yours faithfully.



Mr. Prashant Shrikrishna Karkare

Executive Director

DIN: 06572686

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

-

Part A- Details of the Acquisition


Name of the Target Company (TC)	Goldline Pharmaceutical Limited		
Name(s) of the Acquirer	Mr. Prashant Shrikrishna Karkare		
Whether the Acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of Target Company are Listed	BSE Limited (BSE)		
Details of the acquisition / disposal as follows	Number	% w.r.t. Total Share / Voting Capital	% w.r.t. Total Diluted Share / Voting Capital
Before the acquisition / disposal under consideration, holding of:			
a) Shares carrying voting rights	3	0.00%	0.00%
b) Shares in the nature of encumbrance (pledge / lien / non-disposal undertaking / others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e) Total (a+b+c+d)	3	0.00%	0.00%

Details of Acquisition / Sale	Number	% w.r.t. Total Share / Voting Capital	% w.r.t. Total Diluted Share / Voting Capital
a) Shares carrying voting rights acquired / sold	27000	0.28%	0.28%
b) VRs acquired / sold otherwise than by equity shares	Nil	Nil	Nil
c) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold	Nil	Nil	Nil
d) Shares encumbered / invoked / released by the acquirer	Nil	Nil	Nil
e) Total (a+b+c+d)	27000	0.28%	0.28%
After the Acquisition / Sale, holding of:	Number	% w.r.t. Total Share / Voting Capital	% w.r.t. Total Diluted Share / Voting Capital
a) Shares carrying voting rights acquired	27003	0.28%	0.28%
b) Shares encumbered with the acquirer	Nil	Nil	Nil
c) VRs otherwise than by equity shares	Nil	Nil	Nil
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e) Total (a+b+c+d)	27003	0.28%	0.28%
Mode of Acquisition / Sale (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer, etc.)	Open Market Purchase		
Date of Acquisition / Sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is Applicable	28 th July, 2026		

Equity share capital / total voting capital of the TC before the said acquisition / sale	9600000 Equity Shares
Equity share capital/ total voting capital of the TC after the said acquisition / sale	9600000 Equity Shares
Total diluted share/voting capital of the TC after the said acquisition / sale	Nil

NOTE:

1. I, Prashant Shrikrishna Karkare have purchased 27000 equity shares of Goldline Pharmaceutical Limited through Open Market Purchase.



Mr. Prashant Shrikrishna Karkare

Executive Director

DIN: 06572686

Date: 28th July, 2026

Place: Nagpur